• 4435 Citations
19982020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

My research interest is developing new therapeutic agents for pancreatic cancer. The mammalian target of rapamycin (mTOR) is a downstream mediator in the phosphatidylinositol 3-kinase (PI3K) pathway that regulates cell proliferation, cell survival and angiogenesis in cancer. We hypothesize that combined blockade of the converging pathways can yield a better anti-tumor activity. Currently, we are in the process of examining the clinical benefit of double blockade with a phase I clinical study of the mTOR inhibitor and the EGFR inhibitor in recurrent/refractory malignancies. Furthermore, we are evaluating the potential predictive factors for treatment response and exploring the mechanism of treatment resistance.

Areas of Clinical Interest

gastrointestinal cancer, pancreatic cancer

Fingerprint Dive into the research topics where Andrea Wang-Gillam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation

Hassanzadeh, C., Rudra, S., Bommireddy, A., Hawkins, W. G., Wang-Gillam, A., Fields, R. C., Cai, B., Park, J., Green, O., Roach, M., Henke, L. & Kim, H., 2020, (Accepted/In press) In : Advances in Radiation Oncology.

Research output: Contribution to journalArticle

Open Access
  • FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial

    Park, H., Jin, R. U., Wang-Gillam, A., Suresh, R., Rigden, C., Amin, M., Tan, B. R., Pedersen, K. S., Lim, K. H., Trikalinos, N. A., Acharya, A., Copsey, M. L., Navo, K. A., Morton, A. E., Gao, F. & Lockhart, A. C., 2020, (Accepted/In press) In : JAMA oncology.

    Research output: Contribution to journalArticle

  • Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial

    MacArulla Mercadé, T., Chen, L. T., Li, C. P., Siveke, J. T., Cunningham, D., Bodoky, G., Blanc, J. F., Lee, K. H., Dean, A., Belanger, B. & Wang-Gillam, A., Jan 1 2020, In : Pancreas. 49, 1, p. 62-75 14 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma

    Grierson, P., Teague, A., Suresh, R., Lim, K. H., Amin, M., Pedersen, K., Tan, B., Huffman, J., Boice, N., Du, L., Liu, J., Lockhart, A. C. & Wang-Gillam, A., Feb 1 2020, In : Journal of Gastrointestinal Oncology. 11, 1, p. 61-67 7 p.

    Research output: Contribution to journalArticle

  • TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations

    Dodhiawala, P. B., Khurana, N., Zhang, D., Cheng, Y., Li, L., Wei, Q., Seehra, K., Jiang, H., Grierson, P. M., Wang-Gillam, A. & Lim, K. H., Sep 1 2020, In : Journal of Clinical Investigation. 130, 9, p. 4771-4790 20 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations